Nimbus Therapeutics
Pharmaceutical companies
Since 2009
USA
Cambridge (Massachusetts)
Nimbus Therapeutics - Applies deep structure drug discovery expertise to create new small molecules for serious and poorly studied human diseases in metabolism, oncology and immunology.
History
2022: Takeda acquires Nimbus Therapeutics for $6 billion
On December 13, 2022, Takeda entered into an agreement to acquire the allosteric tyrosine kinase 2 (TYK2) inhibitor Nimbus Therapeutics for $6 billion, NDI-034858. Oral therapy is used to treat a variety of autoimmune diseases. Read more here.
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |